122828-28-8

Basic information

• Product Name: 2-benzylhexahydrocyclopenta[C]pyrrole-4-(1H)-one oxime
• Synonyms: 2-benzylhexahydrocyclopenta[C]pyrrole-4-(1H)-one oxime
• CAS NO: 122828-28-8
• Molecular Weight: 230.31
• Mol File: 122828-28-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-benzylhexahydrocyclopenta[C]pyrrole-4-(1H)-one oxime(CAS DataBase Reference)
• NIST Chemistry Reference: 2-benzylhexahydrocyclopenta[C]pyrrole-4-(1H)-one oxime(122828-28-8)
• EPA Substance Registry System: 2-benzylhexahydrocyclopenta[C]pyrrole-4-(1H)-one oxime(122828-28-8)

Safety Data

• Hazardous Substances Data: 122828-28-8(Hazardous Substances Data)

Upstream product

• 93102-05-7 N-benzyl-N-(methoxymethyl)-N-[(trimethylsilyl)methyl]amine 
• 930-30-3 cyclopent-2-enone 
• 185692-51-7 7-Benzyl-2-oxo-7-azabicyclo[3.3.0]octane 

Downstream Products

• 186201-60-5 (+/-)-(3aR,4R,6aS)-2-(phenylmethyl)octahydrocyclopenta[c]pyrrol-4-amine 
• 186201-60-5 (+/-)-(3aR,4S,6aS)-2-(phenylmethyl)octahydrocyclopenta[c]pyrrol-4-amine 
• 851526-87-9 2-benzylhexahydro-1H-pyrrolo[3,4-c]pyridine-4(2H)-one 

Relevant articles and documents

Moxifloxacin of a kind of hydrochloric acid and its preparation method like structure

The invention provides a novel moxifloxacin hydrochloride structural analog 1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-7-(4-oxo hexahydro-1H-pyrrolo[3,4-c] pyridine-6(2H)yl)-1,4-dihydroquinoline-3-carboxylic acid (I), a preparation method of the analog, and a

Substituted diazabicycloalkane derivatives

Compounds of formula (I) [in-line-formulae]Z-Ar1—Ar2??(I) [/in-line-formulae] wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.